Priority Topics and Scope
We seek manuscripts that provide clear clinical or mechanistic insights into chemotherapy and cancer pharmacology. Studies should demonstrate methodological rigor, transparent reporting, and relevance to patient outcomes.
Priority areas include drug development, chemotherapy combinations, resistance mechanisms, therapeutic drug monitoring, pharmacogenomics, dosing optimization, and supportive care interventions that reduce toxicity and improve quality of life.
Research that bridges bench to bedside and informs clinical guidelines is especially valued. We welcome replication, negative, and real world studies that clarify therapeutic effectiveness.
We also encourage submissions that evaluate access, affordability, and equity in chemotherapy delivery across global settings.
Manuscripts should include clear descriptions of patient populations, endpoints, and statistical methods so findings can be translated into clinical practice and policy.
Studies with robust methodology, multicenter collaboration, or pragmatic trial designs are encouraged, particularly when they address gaps in evidence for high burden cancers.
Transparent data availability statements and adherence to reporting guidelines improve review efficiency and reader confidence.
We welcome well designed trials and observational studies that report adverse events, dosing modifications, and patient reported outcomes to support real world decision making in oncology.
Submissions that address survivorship and long term toxicity monitoring are also encouraged.
Clear reporting of treatment schedules and dose intensity improves clinical applicability.
Case reports with clear learning value and ethics approval are considered.
Robust translational framing improves clinical uptake.
Clinical Oncology
Trials, comparative effectiveness studies, and observational analyses on chemotherapy outcomes across tumor types.
Translational and Preclinical
Mechanistic research on drug resistance, tumor microenvironment interactions, and novel therapeutic targets.
Pharmacology and Dosing
PK and PD modeling, pharmacogenomics, and therapeutic drug monitoring to optimize safety and efficacy.
Health Systems and Implementation
Studies on chemotherapy delivery models, adherence, access barriers, and cost effectiveness.
Biomarkers and Response Prediction
Predictive biomarkers, companion diagnostics, and response monitoring to guide treatment selection.
Special Issues
Submissions aligned with active special issues receive thematic visibility and coordinated promotion.
